SCHEMBL2686703

SCHEMBL2686703

CN(c1cscn1)[C@@H](Cc1ccc(F)cc1)C(=O)Nc1cnc(-c2ccncc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR142 Q7Z601 8/20 0.47
▸ PRKACA P17612 2/20 0.40
▸ ROCK1 Q13464 2/20 0.40
▸ CYP1A2 P05177 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ PSMD14 O00487 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ MCL1 Q07820 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CDC7 O00311 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3712218 1.00 GPR142 (0.47) GPR142PRKACAROCK1CYP1A2CYP3A4
SCHEMBL2685591 0.91 GPR142 (0.57) GPR142PRKACAROCK1NOX1
SCHEMBL2686560 0.80 GPR142 (0.50) GPR142PRKACAROCK1MAPT
SCHEMBL2684844 0.78 GPR142 (0.55) GPR142PRKACAROCK1CYP1A2CYP3A4
SCHEMBL2684847 0.78 GPR142 (0.55) GPR142PRKACAROCK1CYP1A2CYP3A4
SCHEMBL2686714 0.78 GPR142 (0.62) GPR142
SCHEMBL2686708 0.78 GPR142 (0.62) GPR142
SCHEMBL2691240 0.78 GPR142 (0.42) GPR142PRKACAROCK1
SCHEMBL2685860 0.77 GPR142 (0.62) GPR142KDM4EALDH1A1HPGDMAPT
SCHEMBL2685412 0.76 GPR142 (0.51) GPR142PRKACAROCK1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US claimed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885PRKACA 2333/4885ROCK1 4103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback